A recent article in the New York Times, How Poor Sleep Affects Your Risk of Dementia, summarizes some recent findings showing both excessively short and long sleep, as well as…
Read More
Message from the Director Dear Friends of UCI MIND, Please enjoy the latest issue of MIND Matters from UCI MIND. In this Spring issue, we highlight a number of…
Read More
Today, the US Food and Drug Administration granted full clinical approval to Eli Lilly to market donanemab, brand name KISUNLA, for the treatment of early Alzheimer’s disease, including Mild Cognitive…
Read More
A June 17 article in the Los Angeles Times highlighted an important safety risk associated with the new class of medications recently approved for treating Alzheimer’s disease (https://www.latimes.com/science/story/2024-06-17/alzheimers-drug-has-potent...
Read More
Today, the FDA convened its Peripheral and Central Nervous System Drugs Advisory Committee to review the data from pivotal clinical trials of donanemab, a monoclonal antibody against the beta amyloid…
Read More
For patients experiencing cognitive decline due to Alzheimer’s Disease (AD), choosing the most appropriate treatment course at the right time is of great importance. A key element to these decisions…
Read More
The FDA today announced that it will convene an advisory panel to review the data submitted to support potential approval of donanemab, a monoclonal antibody against the beta amyloid protein…
Read More